Synergistic Polygala Extract System for Personalized ADHD Treatment

Publication ID: 24-11857592_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Polygala Extract System for Personalized ADHD Treatment,” Published Technical Disclosure No. 24-11857592_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857592_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,592.

Summary of the Inventive Concept

A novel system integrating Radix Polygalae extract with AI, IoT, and blockchain technologies to provide personalized treatment recommendations and optimize ADHD symptom management.

Background and Problem Solved

The original patent disclosed the use of Radix Polygalae extract for treating ADHD, but its efficacy and treatment outcomes varied among individuals. The new inventive concept addresses this limitation by combining the extract with advanced technologies to create a more effective and personalized treatment system.

Detailed Description of the Inventive Concept

The system comprises a wearable device with a biosensor for monitoring physiological data, a mobile application for processing the data and providing personalized treatment recommendations, and an oral composition comprising an effective amount of Radix Polygalae extract. The system uses machine learning algorithms to analyze genomic data and identify genetic markers associated with ADHD, enabling targeted treatment. Additionally, a blockchain-based system tracks the supply chain of Radix Polygalae extract, ensuring authenticity and quality. The system's AI-powered optimization of the extract's composition further enhances therapeutic efficacy.

Novelty and Inventive Step

The new claims introduce the novel combination of Radix Polygalae extract with AI, IoT, and blockchain technologies, which provides a synergistic effect in treating ADHD. This integration enables personalized treatment recommendations, optimized composition, and secure supply chain management, distinguishing the inventive concept from the original patent.

Alternative Embodiments and Variations

Alternative embodiments include using different types of biosensors, integrating with electronic health records, or incorporating additional AI-powered analytics for more accurate treatment recommendations. Variations of the system could target specific ADHD subtypes or be adapted for use in different populations, such as children or adults.

Potential Commercial Applications and Market

The Synergistic Polygala Extract System has significant commercial potential in the ADHD treatment market, which is expected to grow significantly in the coming years. The system's personalized approach and advanced technologies could attract patients seeking more effective and targeted treatments, as well as healthcare providers and payers looking to improve treatment outcomes and reduce costs.

CPC Classifications

SectionClassGroup
A A61 A61K36/69
A A61 A61K9/0053
A A61 A61K9/485
A A61 A61K9/4825
A A61 A61K9/4858
A A61 A61K47/02
A A61 A61K47/12
A A61 A61P25/28
A A61 A61K2236/333

Original Patent Information

Patent NumberUS 11,857,592
TitlePolygala extract for the treatment of attention-deficit hyperactivity disorder
Assignee(s)BioLite Inc.